Reasonably good Q2, despite underlying challenges/risks
13/05/22 -"Despite the supply-chain challenges, CZM reported a reasonably good set of Q2 21/22 results. Both segments reported double-digit growth and order intake was impressive. Unlike most of the MedTech ..."
Pages
64
Language
English
Published on
13/05/22
You may also be interested by these reports :
14/10/25
Since our last Carl Zeiss Meditec (CZM; BUY; Germany) idea kicker in June 2024, a lot has gone wrong for the German Medtech. Results weakened due to: ...
10/10/25
Key conclusions: Chinese manufacturers can produce Meta Rayban-like glasses for €25. The margin dilution impact of Meta Ray-Ban is probably lower ...
10/10/25
We have removed the long term margin dilution from Meta Ray-Ban in our model as we think the dilution won’t be as significant as we had previously ...
08/10/25
Sartorius is scheduled to report its Q3 2025 earnings on the 16th of October. Interestingly, the stock has surged c. 14% from 30 September to 7 ...